MFSD3

Across TCGA pan-cancer cohorts, MFSD3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MFSD3 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MFSD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MFSD3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and CCRCC are the cancer types where MFSD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.883	0.487	.019	8	view →
GBM	OS	Median	All	0.881	0.724	.041	5	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.838	.038	4	view →
LSCC	DFS	Median	All	0.570	1.000	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MFSD3–HNSC (DFS)

Open the HNSC breakdown →